121 related articles for article (PubMed ID: 38747288)
1. Posttranslational protein modifications as gatekeepers of cancer immunogenicity.
Marchese E; Demehri S
J Clin Invest; 2024 May; 134(10):. PubMed ID: 38747288
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
Zhu Y; Banerjee A; Xie P; Ivanov AA; Uddin A; Jiao Q; Chi JJ; Zeng L; Lee JY; Xue Y; Lu X; Cristofanilli M; Gradishar WJ; Henry CJ; Gillespie TW; Bhave MA; Kalinsky K; Fu H; Bahar I; Zhang B; Wan Y
J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38530357
[TBL] [Abstract][Full Text] [Related]
3. CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer.
Petruk N; Tuominen S; Åkerfelt M; Mattsson J; Sandholm J; Nees M; Yegutkin GG; Jukkola A; Tuomela J; Selander KS
Sci Rep; 2021 Mar; 11(1):6035. PubMed ID: 33727591
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy induces enrichment of CD47
Samanta D; Park Y; Ni X; Li H; Zahnow CA; Gabrielson E; Pan F; Semenza GL
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1239-E1248. PubMed ID: 29367423
[TBL] [Abstract][Full Text] [Related]
5. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy and mechanism of CD73-TGFβ dual-blockade in a mouse model of triple-negative breast cancer.
Xing Y; Ren ZQ; Jin R; Liu L; Pei JP; Yu K
Acta Pharmacol Sin; 2022 Sep; 43(9):2410-2418. PubMed ID: 35082394
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
Buisseret L; Pommey S; Allard B; Garaud S; Bergeron M; Cousineau I; Ameye L; Bareche Y; Paesmans M; Crown JPA; Di Leo A; Loi S; Piccart-Gebhart M; Willard-Gallo K; Sotiriou C; Stagg J
Ann Oncol; 2018 Apr; 29(4):1056-1062. PubMed ID: 29145561
[TBL] [Abstract][Full Text] [Related]
8. CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer.
Cerbelli B; Botticelli A; Pisano A; Pernazza A; Campagna D; De Luca A; Ascierto PA; Pignataro MG; Pelullo M; Rocca CD; Marchetti P; Fortunato L; Costarelli L; d'Amati G
Virchows Arch; 2020 Apr; 476(4):569-576. PubMed ID: 31853625
[TBL] [Abstract][Full Text] [Related]
9. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer.
Chen Q; Pu N; Yin H; Zhang J; Zhao G; Lou W; Wu W
J Cell Mol Med; 2020 Aug; 24(15):8674-8686. PubMed ID: 32643277
[TBL] [Abstract][Full Text] [Related]
10. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
[TBL] [Abstract][Full Text] [Related]
11. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.
Neo SY; Yang Y; Record J; Ma R; Chen X; Chen Z; Tobin NP; Blake E; Seitz C; Thomas R; Wagner AK; Andersson J; de Boniface J; Bergh J; Murray S; Alici E; Childs R; Johansson M; Westerberg LS; Haglund F; Hartman J; Lundqvist A
J Clin Invest; 2020 Mar; 130(3):1185-1198. PubMed ID: 31770109
[TBL] [Abstract][Full Text] [Related]
12. A Novel Specific Anti-CD73 Antibody Inhibits Triple-Negative Breast Cancer Cell Motility by Regulating Autophagy.
Qiao Z; Li X; Kang N; Yang Y; Chen C; Wu T; Zhao M; Liu Y; Ji X
Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30823477
[TBL] [Abstract][Full Text] [Related]
13. Tumor Extracellular Matrix Stiffness Promptly Modulates the Phenotype and Gene Expression of Infiltrating T Lymphocytes.
Chirivì M; Maiullari F; Milan M; Presutti D; Cordiglieri C; Crosti M; Sarnicola ML; Soluri A; Volpi M; Święszkowski W; Prati D; Rizzi M; Costantini M; Seliktar D; Parisi C; Bearzi C; Rizzi R
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070750
[TBL] [Abstract][Full Text] [Related]
14. Identification of a regulatory Vδ1 gamma delta T cell subpopulation expressing CD73 in human breast cancer.
Chabab G; Barjon C; Abdellaoui N; Salvador-Prince L; Dejou C; Michaud HA; Boissière-Michot F; Lopez-Crapez E; Jacot W; Pourquier D; Bonnefoy N; Lafont V
J Leukoc Biol; 2020 Jun; 107(6):1057-1067. PubMed ID: 32362028
[TBL] [Abstract][Full Text] [Related]
15. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
[TBL] [Abstract][Full Text] [Related]
16. Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints.
Baghbani E; Noorolyai S; Shanehbandi D; Mokhtarzadeh A; Aghebati-Maleki L; Shahgoli VK; Brunetti O; Rahmani S; Shadbad MA; Baghbanzadeh A; Silvestris N; Baradaran B
Life Sci; 2021 Oct; 282():119826. PubMed ID: 34265363
[TBL] [Abstract][Full Text] [Related]
17. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.
Beavis PA; Divisekera U; Paget C; Chow MT; John LB; Devaud C; Dwyer K; Stagg J; Smyth MJ; Darcy PK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14711-6. PubMed ID: 23964122
[TBL] [Abstract][Full Text] [Related]
18. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts.
Gao Z; Wang L; Song Z; Ren M; Yang Y; Li J; Shen K; Li Y; Ding Y; Yang Y; Zhou Y; Wei C; Gu J
Front Immunol; 2022; 13():954039. PubMed ID: 36131912
[TBL] [Abstract][Full Text] [Related]
20. SNAI1-dependent upregulation of CD73 increases extracellular adenosine release to mediate immune suppression in TNBC.
Hasmim M; Xiao M; Van Moer K; Kumar A; Oniga A; Mittelbronn M; Duhem C; Chammout A; Berchem G; Thiery JP; Volpert M; Hollier B; Noman MZ; Janji B
Front Immunol; 2022; 13():982821. PubMed ID: 36159844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
